Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Mary K. Beard. (2012) Bisphosphonate therapy for osteoporosis: combining optimal fracture risk reduction with patient preference. Current Medical Research and Opinion 28:1, pages 141-147.
Read now
Read now
Véronique Rabenda & Jean-Yves Reginster. (2010) Overcoming problems with adherence to osteoporosis medication. Expert Review of Pharmacoeconomics & Outcomes Research 10:6, pages 677-689.
Read now
Read now
Kristina Casadei & Carolyn Becker. (2009) Once-monthly risedronate for postmenopausal osteoporosis. International Journal of Women's Health 1, pages 1-9.
Read now
Read now
Deborah T. Gold, Haian Trinh & Wael Safi. (2009) Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy. Current Medical Research and Opinion 25:8, pages 1831-1839.
Read now
Read now
María J Moro-Álvarez & Manuel Díaz-Curiel. (2008) Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis. Clinical Interventions in Aging 3:2, pages 227-232.
Read now
Read now
Thomas W. Weiss, Scott C. Henderson, Colleen A. McHorney & Joyce A. Cramer. (2007) Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills. Current Medical Research and Opinion 23:9, pages 2193-2203.
Read now
Read now
Colleen A. McHorney, John T. Schousboe, Richard R. Cline & Thomas W. Weiss. (2007) The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates. Current Medical Research and Opinion 23:12, pages 3137-3152.
Read now
Read now
Articles from other publishers (17)
Laura Canals-Ruiz, Marta Comellas & Luís Lizán. (2021) Preferences, satisfaction and decision-making processes in osteoporosis treatment: a systematic review of the literature. Journal of Comparative Effectiveness Research 10:8, pages 629-645.
Crossref
Crossref
L. Chou, P. Shamdasani, A. M. Briggs, F. M. Cicuttini, K. Sullivan, K. L. M. D. Seneviwickrama & A. E. Wluka. (2017) Systematic scoping review of patients’ perceived needs of health services for osteoporosis. Osteoporosis International 28:11, pages 3077-3098.
Crossref
Crossref
Deborah T. Gold. 2016. The Duration and Safety of Osteoporosis Treatment. The Duration and Safety of Osteoporosis Treatment
239
253
.
Hideaki Kishimoto & Masayuki Maehara. (2015) Compliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISA. Archives of Osteoporosis 10:1.
Crossref
Crossref
Mickaël Hiligsmann, Sandrine P. G. Bours & Annelies Boonen. (2015) A Review of Patient Preferences for Osteoporosis Drug Treatment. Current Rheumatology Reports 17:9.
Crossref
Crossref
Deborah T. Gold. 2013. Osteoporosis. Osteoporosis
1909
1921
.
Michael R. McClung, Claude-Laurent Benhamou, Zulema Man, Witold Tlustochowicz, Jose R. Zanchetta, Rachelle Eusebio, Ana M. Balske, Ellen Matzkin, Wojciech P. Olszynski, Robert Recker & Pierre D. Delmas. (2012) A Novel Monthly Dosing Regimen of Risedronate for the Treatment of Postmenopausal Osteoporosis: 2-Year Data. Calcified Tissue International 92:1, pages 59-67.
Crossref
Crossref
Deborah T. Gold. (2011) Understanding Patient Compliance and Persistence with Osteoporosis Therapy. Drugs & Aging 28:4, pages 249-255.
Crossref
Crossref
Stefka Kuzmanova, Panayot Solakov & Mariela Geneva-Popova. (2011) Adherence to Bisphosphonate Therapy in Postmenopausal Osteoporotic Women. Folia Medica 53:3.
Crossref
Crossref
Stuart L. Silverman. (2010) Osteoporosis Therapies: Evidence from Health-Care Databases and Observational Population Studies. Calcified Tissue International 87:5, pages 375-384.
Crossref
Crossref
Debby den Uyl, Piet P. M. M. Geusens, Frank N. R. van Berkum, Harry H. M. L. Houben, Max C. Jebbink & Willem F. Lems. (2009) Patient preference and acceptability of calcium plus vitamin D3 supplementation: a randomised, open, cross-over trial. Clinical Rheumatology 29:5, pages 465-472.
Crossref
Crossref
Valentina I. Petkov & Melissa I. Williams. 2010. Osteoporosis. Osteoporosis
605
620
.
Darko Kastelan, Petar Lozo, Doris Stamenkovic, Blazenka Miskic, Tonko Vlak, Zeljka Kolak, Jasminka Milas Ahic, Velimir Altabas, Zeljka Crncevic Orlic & Mirko Korsic. (2008) Preference for weekly and monthly bisphosphonates among patients with postmenopausal osteoporosis: results from the Croatian PROMO Study. Clinical Rheumatology 28:3, pages 321-326.
Crossref
Crossref
M. Sosa Henríquez & M.J. Gómez de Tejada Romero. (2009) La medicina basada en la evidencia y los fármacos aprobados para el tratamiento de la osteoporosis. Papel del calcio y la vitamina D. Revista Clínica Española 209:1, pages 25-36.
Crossref
Crossref
P. D. Delmas, C. L. Benhamou, Z. Man, W. Tlustochowicz, E. Matzkin, R. Eusebio, J. Zanchetta, W. P. Olszynski, R. R. Recker & M. R. McClung. (2007) Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results. Osteoporosis International 19:7, pages 1039-1045.
Crossref
Crossref
DEBORAH T. GOLD & SAMANTHA SOLIMEO. 2008. Osteoporosis. Osteoporosis
1547
1553
.
Deborah T Gold & Stuart L Silverman. (2007) Compliance and persistence with osteoporosis therapies: we can do better. Future Rheumatology 2:5, pages 443-445.
Crossref
Crossref